Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases

Neurogastroenterology and Motility

Volumn 27, Issue 8, 2015, Pages 1057-1068

  Jarmuz, A ^a   Zielinska M ^a   Storr, M ^b,c   Fichna, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Center of Endoscopy   (Germany)

Author keywords

Guanylin; Guanylyl cyclase C agonists; Linaclotide; Plecanatide; SP 333; Uroguanylin

Indexed keywords

ANTIINFLAMMATORY AGENT; DRUG METABOLITE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE C RECEPTOR; GUANYLIN; GUANYLYL CYCLASE C AGONIST; LINACLOTIDE; MM 419447; PLECANATIDE; RECEPTOR; SP 333; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; ENTEROTOXIN RECEPTOR; GASTROINTESTINAL HORMONE; NATRIURETIC FACTOR; PEPTIDE; UROGUANYLIN;

ABDOMINAL PAIN; CHRONIC CONSTIPATION; CHRONIC IDIOPATHIC CONSTIPATION; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BIOAVAILABILITY; ENDOCRINE FUNCTION; HUMAN; IDIOPATHIC DISEASE; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; AGONISTS; CONSTIPATION; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL DISEASES; INFLAMMATORY BOWEL DISEASES; MALE; METABOLISM; TRENDS;

CLINICAL TRIALS AS TOPIC; CONSTIPATION; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HORMONES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; NATRIURETIC PEPTIDES; PEPTIDES; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

EID: 84937969535     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12574     Document Type: Review

References (95)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-9.
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
3. Burisch J, Pedersen N, Cukovic-Cavka S, Turk N, Kaimakliotis I, Duricova D, Shonová O, Vind I et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis 2014; 20: 36-46.
4. Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Avnstrøm S, Vinding KK et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J Crohns Colitis 2014; 8: 1506-15.
5. Brierley SM. Guanylate cyclase-C receptor activation: unexpected biology. Curr Opin Pharmacol 2012; 12: 632-40.
6. Lin JE, Valentino M, Marszalowicz G, Magee MS, Li P, Snook AE, Stoecker BA, Chang C et al. Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. Toxins (Basel) 2010; 2: 2028-54.
7. Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther 2012; 91: 44-59.
8. Pitari GM. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther 2013; 7: 351-60.
9. Steinbrecher KA, Cohen MB. Transmembrane guanylate cyclase in intestinal pathophysiology. Curr Opin Gastroenterol 2011; 27: 139-45.
10. Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain. Front Mol Neurosci 2014; 7: 31.
11. Shailubhai K, Comiskey S, Foss JA, Feng R, Barrow L, Comer GM, Jacob GS. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013; 58: 2580-6.
12. Shailubhai K, Foss J, Zhang G, Arjunan KP, Feng R, Comiskey S, Jacob S, Plevy SE. SP-333, a Guanylate Cyclase-C Agonist, Ameliorates DSS-Colitis in Mice Via a Novel Cyclic GMP-Mediated Mechanism (P-198). Poster presentation at: Advances in Inflammatory Bowel Diseases, Crohn's & Colitis Foundation's Clinical & Research Conference, 2012.
13. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52: 375-414.
14. Vaandrager AB. Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C. Mol Cell Biochem 2002; 230: 73-83.
15. Hasegawa M, Hidaka Y, Wada A, Hirayama T, Shimonishi Y. The relevance of N-linked glycosylation to the binding of a ligand to guanylate cyclase C. Eur J Biochem 1999; 263: 338-46.
16. Fawcus K, Gorton VJ, Lucas ML, McEwan GT. Stimulation of three distinct guanylate cyclases induces mucosal surface alkalinisation in rat small intestine in vitro. Comp Biochem Physiol A Physiol 1997; 118: 291-5.
17. + exchanger in an intestinal cellular model. Cell Physiol Biochem 2011; 28: 733-42.
18. Cuthbert AW, Hickman ME, MacVinish LJ, Evans MJ, Colledge WH, Ratcliff R, Seale PW, Humphrey PP. Chloride secretion in response to guanylin in colonic epithelial from normal and transgenic cystic fibrosis mice. Br J Pharmacol 1994; 112: 31-6.
19. 3-secretion by uroguanylin. Am J Physiol 1998; 274(4 Pt 1): G633-44.
20. Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, Gardner P. Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 1994; 13: 1065-72.
21. Guba M, Kuhn M, Forssmann WG, Classen M, Gregor M, Seidler U. Guanylin strongly stimulates rat duodenal. Gastroenterology 1996; 111: 1558-68.
22. Vaandrager AB, Bot AG, de Jonge HR. Guanosine 3', 5'-cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine. Gastroenterology 1997; 112: 437-43.
23. Vaandrager AB, Smolenski A, Tilly BC, Houtsmuller AB, Ehlert EM, Bot AG, Edixhoven M, Boomaars WE et al. Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl- channel activation. Proc Natl Acad Sci U S A 1998; 95: 1466-71.
24. Vaandrager AB, Bot AG, Ruth P, Pfeifer A, Hofmann F, de Jonge HR. Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon. Gastroenterology 2000; 118: 108-14.
25. Sindic A. Current understanding of guanylin peptides actions. ISRN Nephrol 2013; 2013: 813648. doi:10.5402/2013/813648.
26. Magert HJ, Reinecke M, David I, Raab HR, Adermann K, Zucht HD, Hill O, Hess R et al. Uroguanylin: gene structure, expression, processing as a peptide hormone, and co-storage with somatostatin in gastrointestinal D-cells. Regul Pept 1998; 73: 165-76.
27. Hill O, Kuhn M, Zucht HD, Cetin Y, Kulaksiz H, Adermann K, Klock G, Rechkemmer G et al. Analysis of the human guanylin gene and the processing and cellular localization of the peptide. Proc Natl Acad Sci U S A 1995; 92: 2046-50.
28. de Sauvage FJ, Keshav S, Kuang WJ, Gillett N, Henzel W, Goeddel DV. Precursor structure, expression, and tissue distribution of human guanylin. Proc Natl Acad Sci U S A 1992; 89: 9089-93.
29. Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, Chin DT, Tompkins JA et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A 1993; 90: 10464-8.
30. London RM, Krause WJ, Fan X, Eber SL, Forte LR. Signal transduction pathways via guanylin and uroguanylin in stomach and intestine. Am J Physiol 1997; 273(1 Pt 1): G93-105.
31. Wiegand RC, Kato J, Huang MD, Fok KF, Kachur JF, Currie MG. Human guanylin: cDNA isolation, structure, and activity. FEBS Lett 1992; 311: 150-4.
32. Kita T, Smith CE, Fok KF, Duffin KL, Moore WM, Karabatsos PJ, Kachur JF, Hamra FK et al. Characterization of human uroguanylin: a member of the guanylin peptide family. Am J Physiol 1994; 266(2 Pt 2): F342-8.
33. Miyazato M, Nakazato M, Matsukura S, Kangawa K, Matsuo H. Uroguanylin gene expression in the alimentary tract and extra-gastrointestinal tissues. FEBS Lett 1996; 398: 170-4.
34. Mueller T, Dieplinger B. The guanylin peptide family and the proposed gastrointestinal-renal natriuretic signaling axis. Kidney Int 2012; 82: 1253-5.
35. Whitaker TL, Witte DP, Scott MC, Cohen MB. Uroguanylin and guanylin: distinct but overlapping patterns of messenger RNA expression in mouse intestine. Gastroenterology 1997; 113: 1000-6.
36. Cetin Y, Kuhn M, Kulaksiz H, Adermann K, Bargsten G, Grube D, Forssmann WG. Enterochromaffin cells of the digestive system: cellular source of guanylin, a guanylate cyclase-activating peptide. Proc Natl Acad Sci U S A 1994; 91: 2935-9.
37. Nakazato M, Yamaguchi H, Date Y, Miyazato M, Kangawa K, Goy MF, Chino N, Matsukura S et al. Tissue distribution, cellular source, and structural analysis of rat immunoreactive uroguanylin. Endocrinology 1998; 139: 5247-54.
38. Perkins A, Goy MF, Li Z. Uroguanylin is expressed by enterochromaffin cells in the rat gastrointestinal tract. Gastroenterology 1997; 113: 1007-14.
39. Kinoshita H, Fujimoto S, Nakazato M, Yokota N, Date Y, Yamaguchi H, Hisanaga S, Eto T, et al. Urine and plasma levels of uroguanylin and its molecular forms in renal diseases. Kidney Int 1997; 52: 1028-34.
40. Hamra FK, Eber SL, Chin DT, Currie MG, Forte LR. Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. Proc Natl Acad Sci U S A 1997; 94: 2705-10.
41. Potthast R, Ehler E, Scheving LA, Sindic A, Schlatter E, Kuhn M. High salt intake increases uroguanylin expression in mouse kidney. Endocrinology 2001; 142: 3087-97.
42. Li Z, Knowles JW, Goyeau D, Prabhakar S, Short DB, Perkins AG, Goy MF. Low salt intake down-regulates the guanylin signaling pathway in rat distal colon. Gastroenterology 1996; 111: 1714-21.
43. Hamra FK, Krause WJ, Eber SL, Freeman RH, Smith CE, Currie MG, Forte LR. Opossum colonic mucosa contains uroguanylin and guanylin peptides. Am J Physiol 1996; 270(4 Pt 1): G708-16.
44. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008; 5: e54.
45. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12: 319-30.
46. Bachmann O, Seidler U. News from the end of the gut-how the highly segmental pattern of colonic HCO(3)(-) transport relates to absorptive function and mucosal integrity. Biol Pharm Bull 2011; 34: 794-802.
47. Steinbrecher KA, Tuohy TM, Heppner GK, Scott MC, Witte DP, Groden J, Cohen MB. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun 2000; 273: 225-30.
48. Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab Invest 1998; 78: 101-8.
49. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci U S A 2001; 98: 7846-51.
50. Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 2000; 60: 5151-7.
51. Cagir B, Gelmann A, Park J, Fava T, Tankelevitch A, Bittner EW, Weaver EJ, Palazzo JP et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 1999; 131: 805-12.
52. Park J, Schulz S, Haaf J, Kairys JC, Waldman SA. Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. Cancer Epidemiol Biomarkers Prev 2002; 11: 739-44.
53. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-63.
54. Locke GR III, Yawn BP, Wollan PC, Melton LJ III, Lydick E, Talley NJ. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. Aliment Pharmacol Ther 2004; 19: 1025-31.
55. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
56. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626-35.
57. Chang L. Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon? Gastroenterology 2006; 130: 596-600.
58. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012; 4: 2783-800.
59. Feng B, La JH, Schwartz ES, Gebhart GF. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1085-98.
60. Park JH, Rhee PL, Kim G, Lee JH, Kim YH, Kim JJ, Rhee JC, Song SY et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 539-46.
61. Rao S, Weber HC. New treatment targets for the management of irritable bowel syndrome. Curr Opin Endocrinol Diabetes Obes 2014; 21: 9-14.
62. Spiller R. Serotonergic agents and the irritable bowel syndrome: what goes wrong? Curr Opin Pharmacol 2008; 8: 709-14.
63. Fichna J, Storr MA. Brain-gut interactions in IBS. Front Pharmacol 2012; 3: 127.
64. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011; 60: 209-18.
65. Gray JR. What is chronic constipation? Definition and diagnosis Can J Gastroenterol 2011; 25 (Suppl. B): 7B-10B.
66. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013; 344: 196-206.
67. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010; 649: 328-35.
68. Thomas RH, Allmond K. Linaclotide (linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation. P T 2013; 38: 154-60.
69. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22: 312-e84.
70. Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3', 5'-monophosphate. Gastroenterology 2013; 145: 1334-46.
71. Miner PB Jr, DeLuca R, De La Portilla M, Padilla E, Koltun W, Wiltz O, Shailubhai K, Jacob GS et al. Plecanatide, a Novel Uroguanylin Analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). Program No. 14. ACG 2014 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology; 2014. Available from: http://www.eventscribe.com/2014/acg/PostersTitles.asp?sort=num&dir=&h=Browse%20by%20Number
72. Krause RA. Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC). ClinicalTrials.gov Identifier: NCT01919697. 2013.
73. Winkle P. Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects. ClinicalTrials.gov Identifier: NCT01705938. 2012.
74. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-24.
75. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
76. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527-36.
77. Sobczak M, Fabisiak A, Murawska N, Wesolowska E, Wierzbicka P, Wlazlowski M, Wójcikowska M, Zatorski H et al. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep 2014; 66: 766-75.
78. Yen EF, Pardi DS. Non-IBD colitides (eosinophilic, microscopic). Best Pract Res Clin Gastroenterol 2012; 26: 611-22.
79. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
80. Cottone M, Renda MC, Mattaliano A, Oliva L, Fries W, Criscuoli V, Modesto I, Scimeca D et al. Incidence of Crohn's disease and CARD15 mutation in a small township in Sicily. Eur J Epidemiol 2006; 21: 887-92.
81. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101: 1559-68.
82. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 1-20.
83. Schirbel A, Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis 2010; 11: 266-76.
84. Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol 2010; 3: 77-86.
85. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
86. Comiskey SJ, Foss JA, Jacob GS, Shailubhai K. Plecanatide, A Guanylate Cyclase-C Agonist, Acts in the Lumen of the Proximal Intestine to Facilitate Normal Bowel Movement in Mice and Monkeys. American College of Gastroenterology Annual Meeting. 2012.
87. Philip BM. The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) (CIBS). ClinicalTrials.gov Identifier: NCT01722318. 2012.
88. Philip BM, Surowitz R, Fogel R, Koltun W, Drossman DA, Camilleri M, Mangel A, Barrow L et al. Plecanatide, a novel guanylate cyclase C receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation: results from a 951 patient, 12 week, multi-center trial. Digestive Disease Week 2013.
89. Shailubhai K, Nefsky B, Masih S, Foss J, Comiskey S, Jacob G, Plevy S. Guanylate cyclase C agonists, a new class of drug candidates for treatment of inflammatory bowel disease. Am J Gastroenterol 2011.
90. Min/+ mice. Am J Gastroenterol 2011.
91. Sanders DS. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 2005; 58: 568-72.
92. Moens E, Veldhoen M. Epithelial barrier biology: good fences make good neighbours. Immunology 2012; 135: 1-8.
93. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379-400.
94. Graham Z, Krishna Priya A, Foss J, Comiskey S, Shailubhai K. SP-333, a proteolysis-resistant agonist of guanylate cyclase-C, inhibits activation of NF-kB and supress production of inflammatory cytokines to ameliorate DSS-induced colitis in mice. Am J Gastroenterol 2012.
95. Renata T. Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC). ClinicalTrials.gov Identifier: NCT01983306. 2013.